Quest Diagnostics Reports Fourth Quarter and Full Year 2024 Financial Results; Provides Guidance for Full Year 2025; Increases Quarterly Dividend 6.7% to $0.80 Per Share
Quest Diagnostics (DGX) reported strong Q4 2024 financial results with revenues of $2.62 billion, up 14.5% year-over-year, and full-year revenues of $9.87 billion, up 6.7%. Q4 reported diluted EPS reached $1.95, increasing 14.7%, while adjusted diluted EPS was $2.23, up 3.7%.
The company completed eight acquisitions in 2024, including LifeLabs in Canada, expanded its health plan access to over 90% of in-network lives nationwide, and grew its Advanced Diagnostics portfolio. For 2025, Quest expects revenues between $10.70-10.85 billion and adjusted diluted EPS of $9.55-9.80.
The Board authorized a 6.7% increase in quarterly dividend to $0.80 per share, marking continuous dividend growth since 2011.
Quest Diagnostics (DGX) ha riportato risultati finanziari solidi per il quarto trimestre del 2024 con ricavi di 2,62 miliardi di dollari, in aumento del 14,5% rispetto all'anno precedente, e ricavi totali per l'anno di 9,87 miliardi di dollari, in crescita del 6,7%. L'EPS diluito riportato per il Q4 ha raggiunto $1,95, con un aumento del 14,7%, mentre l'EPS diluito rettificato è stato di $2,23, in crescita del 3,7%.
L'azienda ha completato otto acquisizioni nel 2024, tra cui LifeLabs in Canada, ha ampliato l'accesso ai propri piani sanitari a oltre il 90% delle persone assicurate a livello nazionale, e ha sviluppato il suo portafoglio di Diagnostica Avanzata. Per il 2025, Quest prevede ricavi tra 10,70 e 10,85 miliardi di dollari e un EPS diluito rettificato di 9,55-9,80 dollari.
Il Consiglio ha autorizzato un incremento del 6,7% nel dividendo trimestrale a $0,80 per azione, segnando una crescita continua del dividendo dal 2011.
Quest Diagnostics (DGX) reportó resultados financieros sólidos para el cuarto trimestre de 2024 con ingresos de 2.62 mil millones de dólares, un aumento del 14.5% interanual, y ingresos totales del año de 9.87 mil millones de dólares, un incremento del 6.7%. El EPS diluido reportado para el cuarto trimestre alcanzó $1.95, aumentando un 14.7%, mientras que el EPS diluido ajustado fue de $2.23, indicando un aumento del 3.7%.
La compañía completó ocho adquisiciones en 2024, incluyendo LifeLabs en Canadá, amplió su acceso a planes de salud a más del 90% de vidas en red en todo el país, y creció su portafolio de Diagnósticos Avanzados. Para 2025, Quest espera ingresos entre 10.70 y 10.85 mil millones de dólares y un EPS diluido ajustado de 9.55-9.80 dólares.
La Junta autorizó un aumento del 6.7% en el dividendo trimestral a $0.80 por acción, marcando un crecimiento continuo del dividendo desde 2011.
퀘스트 진단(Quest Diagnostics, DGX)는 2024년 4분기 재무 결과를 발표했으며, 총 수익은 26억 2천만 달러로 지난해 대비 14.5% 증가했으며, 연간 총 수익은 98억 7천만 달러로 6.7% 증가했습니다. 4분기 희석 주당순이익(EPS)은 $1.95에 달하며, 이는 14.7% 증가한 수치입니다. 조정 희석 주당순이익(EPS)은 $2.23으로 3.7% 증가했습니다.
회사는 2024년에 LifeLabs를 포함하여 8건의 인수를 완료하였고, 전국 90% 이상의 네트워크 생명체에 대한 건강 계획 접근을 확대하였으며 고급 진단 포트폴리오를 성장시켰습니다. 2025년에는 퀘스트가 107억-108억 5천만 달러의 수익과 95.5-98.0 달러의 조정 희석 주당순이익(EPS)을 예상하고 있습니다.
이사회는 분기 배당금을 6.7% 인상하여 주당 $0.80으로 설정하였으며, 이는 2011년 이후 지속적인 배당 성장에 기여하고 있습니다.
Quest Diagnostics (DGX) a annoncé des résultats financiers solides pour le quatrième trimestre 2024, avec des revenus de 2,62 milliards de dollars, en hausse de 14,5 % par rapport à l'année précédente, et des revenus totaux pour l'année de 9,87 milliards de dollars, en croissance de 6,7 %. Le BPA dilué rapporté pour le Q4 a atteint 1,95 $, en augmentation de 14,7 %, tandis que le BPA dilué ajusté était de 2,23 $, en hausse de 3,7 %.
L'entreprise a réalisé huit acquisitions en 2024, y compris LifeLabs au Canada, a élargi l'accès à ses plans de santé à plus de 90 % des personnes couvertes à l'échelle nationale, et a développé son portefeuille de diagnostics avancés. Pour 2025, Quest prévoit des revenus compris entre 10,70 et 10,85 milliards de dollars et un BPA dilué ajusté de 9,55-9,80 dollars.
Le Conseil a autorisé une augmentation de 6,7 % de son dividende trimestriel à 0,80 $ par action, marquant une croissance continue du dividende depuis 2011.
Quest Diagnostics (DGX) berichtete über starke Finanzergebnisse für das vierte Quartal 2024 mit einem Umsatz von 2,62 Milliarden Dollar, was einem Anstieg von 14,5% im Jahresvergleich entspricht, und einem Jahresumsatz von 9,87 Milliarden Dollar, was einem Anstieg von 6,7% entspricht. Der ausgewiesene verwässerte Gewinn pro Aktie (EPS) erreichte $1,95, was einem Anstieg von 14,7% entspricht, während der bereinigte verwässerte EPS bei $2,23 lag, was einem Anstieg von 3,7% entspricht.
Das Unternehmen hat im Jahr 2024 acht Übernahmen abgeschlossen, darunter LifeLabs in Kanada, hat den Zugang zu seinen Gesundheitsplänen auf über 90% der versicherten Personen im ganzen Land ausgeweitet und sein Portfolio an fortschrittlichen Diagnostikverfahren erweitert. Für 2025 erwartet Quest einen Umsatz zwischen 10,70 und 10,85 Milliarden Dollar und einen bereinigten verwässerten Gewinn pro Aktie von 9,55-9,80 Dollar.
Der Vorstand genehmigte eine 6,7%ige Erhöhung der vierteljährlichen Dividende auf $0,80 pro Aktie, was ein fortlaufendes Dividendenwachstum seit 2011 markiert.
- Q4 revenue growth of 14.5% to $2.62 billion
- Full-year revenue increase of 6.7% to $9.87 billion
- Q4 EPS growth of 14.7% to $1.95
- 6.7% dividend increase to $0.80 per share
- Completion of eight strategic acquisitions
- Expansion of health plan access to 90% of in-network lives
- Q4 cash from operations decreased 12.3% to $464 million
- Operating income margin declined 0.2% for full year on adjusted basis
- Capital expenditures increased 73.9% in Q4
Insights
Quest Diagnostics' Q4 results reveal a nuanced growth story. While headline revenue growth of
Strategic acquisitions, particularly LifeLabs in Canada, position Quest for geographic expansion while hospital outreach acquisitions consolidate domestic market share. The expansion to over
Capital allocation shows balanced priorities:
- Strategic M&A deployment
- Increased dividend maintaining 11-year growth streak
- Higher planned capex of
$500 million for 2025
The automation and AI initiatives across three major laboratories signal a forward-looking operational strategy that should drive margin expansion through improved efficiency. The 2025 guidance implies continued momentum with
Quest's strategic expansion in advanced diagnostics, particularly in Alzheimer's testing with p-tau biomarkers and the Haystack MRD program for oncology, positions the company at the forefront of high-growth diagnostic segments. The transition of 75 oncology centers from early access to commercial programs suggests strong market validation for their minimal residual disease testing platform.
The expansion of questhealth.com to 135 tests represents a strategic push into the growing direct-to-consumer testing market, addressing increasing consumer demand for health monitoring and preventive care. The inclusion of specialized tests like Lipoprotein(a) cholesterol testing targets high-value diagnostic needs.
New partnerships with Elevance Health and Sentara Health Plans strengthen Quest's market position by:
- Expanding geographical reach into new markets
- Securing stable revenue streams through in-network arrangements
- Creating barriers to entry for potential competitors
The CDC contract for H5 avian influenza testing demonstrates Quest's strategic importance in public health infrastructure, potentially leading to additional government partnerships and contracts.
- Fourth quarter revenues of
$2.62 billion 14.5% from 2023 - Fourth quarter reported diluted earnings per share ("EPS") of
$1.95 14.7% from 2023; and adjusted diluted EPS of$2.23 3.7% from 2023 - Full year revenues of
$9.87 billion 6.7% from 2023 - Full year reported diluted EPS of
$7.69 2.7% from 2023; and adjusted diluted EPS of$8.93 2.5% from 2023 - Full year 2025 reported diluted EPS expected to be between
$8.34 $8.59 $9.55 $9.80
"In the fourth quarter, we delivered impressive revenue growth of nearly
Mr. Davis continued: "Our guidance for 2025 reflects our confidence in the core strength of our business, continuing robust utilization, and the momentum from acquisitions completed in 2024. These dynamics position us favorably to accelerate revenue and earnings growth in 2025."
Select 2024 full year accomplishments:
- Completed eight acquisitions, including LifeLabs in
Canada and four hospital outreach lab acquisitions. - Extended our health plan access to over
90% of in-network lives nationwide, including in new geographies through collaborations with Elevance Health and Sentara Health Plans, which took effect January 1, 2025. - Grew our Advanced Diagnostics portfolio, adding the sensitive p-tau217 and p-tau181 biomarkers to our AD-Detect blood-based test menu for assessing Alzheimer's disease risk, and launching the first H5 avian influenza test from a commercial laboratory based on a pandemic preparedness contract from the
U.S. Centers for Disease Control and Prevention. - Engaged approximately 75 academic, health system and community oncology centers in our Haystack MRD Early Experience Program, which provided oncologists with advanced access to our Haystack MRD blood test for aiding in the early detection of minimal residual disease from solid tumor cancers. We are now transitioning these organizations to a commercial program and are focused on expanding utilization among oncologists.
- Expanded our questhealth.com consumer-initiated test platform to include approximately 135 tests, including micronutrient deficiencies and high-risk Lipoprotein(a) cholesterol testing.
- Deployed automation and AI technologies across diverse laboratory, customer service and administrative areas, including automating core laboratory processes at three major regional laboratories, improving quality, customer experiences and productivity.
Three Months Ended December 31, | Twelve Months Ended December 31, | ||||||||||
2024 | 2023 | Change | 2024 | 2023 | Change | ||||||
(dollars in millions, except per share data) | |||||||||||
Reported: | |||||||||||
Net revenues | $ 2,621 | $ 2,288 | 14.5 % | $ 9,872 | $ 9,252 | 6.7 % | |||||
Diagnostic information services revenues | $ 2,556 | $ 2,221 | 15.1 % | $ 9,614 | $ 8,976 | 7.1 % | |||||
Revenue per requisition | 0.2 % | 1.3 % | |||||||||
Requisition volume | 13.9 % | 5.5 % | |||||||||
Organic requisition volume | 0.6 % | 0.7 % | |||||||||
Operating income (a) | $ 361 | $ 267 | 35.3 % | $ 1,346 | $ 1,262 | 6.7 % | |||||
Operating income as a percentage of net revenues (a) | 13.8 % | 11.7 % | 2.1 % | 13.6 % | 13.6 % | — % | |||||
Net income attributable to Quest Diagnostics (a) | $ 222 | $ 192 | 15.1 % | $ 871 | $ 854 | 2.0 % | |||||
Diluted EPS (a) | $ 1.95 | $ 1.70 | 14.7 % | $ 7.69 | $ 7.49 | 2.7 % | |||||
Cash provided by operations | $ 464 | $ 527 | (12.3) % | $ 1,334 | $ 1,272 | 4.8 % | |||||
Capital expenditures | $ 123 | $ 72 | 73.9 % | $ 425 | $ 408 | 4.4 % | |||||
Adjusted (a): | |||||||||||
Operating income | $ 409 | $ 338 | 21.2 % | $ 1,541 | $ 1,457 | 5.8 % | |||||
Operating income as a percentage of net revenues | 15.6 % | 14.8 % | 0.8 % | 15.6 % | 15.8 % | (0.2) % | |||||
Net income attributable to Quest Diagnostics | $ 253 | $ 245 | 3.7 % | $ 1,011 | $ 994 | 1.8 % | |||||
Diluted EPS | $ 2.23 | $ 2.15 | 3.7 % | $ 8.93 | $ 8.71 | 2.5 % | |||||
(a) | For further details impacting the year-over-year comparisons related to operating income, operating income as a percentage of net revenues, net income attributable to Quest Diagnostics, and diluted EPS, see note 2 of the financial tables attached below. |
Dividend Increased
Quest Diagnostics' Board of Directors has authorized a
Guidance for Full Year 2025
The company estimates its full year 2025 guidance in the table below. The company has included a presentation that includes additional guidance information on the Events and Presentations page of its investor relations website, which can be found at www.QuestDiagnostics.com/investor.
Low | High | ||
Net revenues | |||
Net revenues increase | 8.4 % | 9.9 % | |
Reported diluted EPS | |||
Adjusted diluted EPS | |||
Cash provided by operations | Approximately | ||
Capital expenditures | Approximately | ||
Note on Non-GAAP Financial Measures
As used in this press release the term "reported" refers to measures under accounting principles generally accepted in
Non-GAAP adjusted measures are presented because management believes those measures are useful adjuncts to GAAP results. Non-GAAP adjusted measures should not be considered as an alternative to the corresponding measures determined under GAAP. Management may use these non-GAAP measures to evaluate our performance period over period and relative to competitors, to analyze the underlying trends in our business, to establish operational budgets and forecasts and for incentive compensation purposes. We believe that these non-GAAP measures are useful to investors and analysts to evaluate our performance period over period and relative to competitors, as well as to analyze the underlying trends in our business and to assess our performance. The additional tables attached below include reconciliations of non-GAAP adjusted measures to GAAP measures.
Conference Call Information
Quest Diagnostics will hold its quarterly conference call to discuss financial results beginning at 8:30 a.m. Eastern Time today. The conference call can be accessed by dialing 888-455-0391 within the
A replay of the call may be accessed online at www.QuestDiagnostics.com/investor or, from approximately 10:30 a.m. Eastern Time on January 30, 2025 until midnight Eastern Time on February 13, 2025, by phone at 866-360-8701 for domestic callers and 203-369-0179 for international callers. Anyone listening to the call is encouraged to read our periodic reports, on file with the Securities and Exchange Commission, including the discussion of risk factors and historical results of operations and financial condition in those reports.
About Quest Diagnostics
Quest Diagnostics works across the healthcare ecosystem to create a healthier world, one life at a time. We provide diagnostic insights from the results of our laboratory testing to empower people, physicians and organizations to take action to improve health outcomes. Derived from one of the world's largest databases of de-identifiable clinical lab results, Quest's diagnostic insights reveal new avenues to identify and treat disease, inspire healthy behaviors and improve healthcare management. Quest Diagnostics annually serves one in three adult Americans and half the physicians and hospitals in
Forward Looking Statements
The statements in this press release which are not historical facts may be forward-looking statements. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date that they are made and which reflect management's current estimates, projections, expectations or beliefs and which involve risks and uncertainties that could cause actual results and outcomes to be materially different. Risks and uncertainties that may affect the future results of the company include, but are not limited to, adverse results from pending or future government investigations, lawsuits or private actions, the competitive environment, the complexity of billing, reimbursement and revenue recognition for clinical laboratory testing, changes in government regulations, changing relationships with customers, payers, suppliers or strategic partners, acquisitions and other factors discussed in the company's most recently filed Annual Report on Form 10-K and in any of the company's subsequently filed Quarterly Reports on Form 10-Q and Current Reports on Form 8-K, including those discussed in the "Business," "Risk Factors," "Cautionary Factors that May Affect Future Results" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of those reports.
This earnings release, including the attached financial tables, is available online in the Newsroom section at www.QuestDiagnostics.com.
ADDITIONAL TABLES FOLLOW
Quest Diagnostics Incorporated and Subsidiaries Consolidated Statements of Operations For the Three and Twelve Months Ended December 31, 2024 and 2023 (in millions, except per share data) (unaudited) | |||||||
Three Months Ended December 31, | Twelve Months Ended December 31, | ||||||
2024 | 2023 | 2024 | 2023 | ||||
Net revenues | $ 2,621 | $ 2,288 | $ 9,872 | $ 9,252 | |||
Operating costs and expenses and other operating income: | |||||||
Cost of services | 1,763 | 1,552 | 6,628 | 6,199 | |||
Selling, general and administrative | 466 | 407 | 1,770 | 1,642 | |||
Amortization of intangible assets | 37 | 27 | 127 | 108 | |||
Other operating (income) expense, net | (6) | 35 | 1 | 41 | |||
Total operating costs and expenses, net | 2,260 | 2,021 | 8,526 | 7,990 | |||
Operating income | 361 | 267 | 1,346 | 1,262 | |||
Other income (expense): | |||||||
Interest expense, net | (65) | (40) | (201) | (152) | |||
Other income, net | 3 | 10 | 30 | 20 | |||
Total non-operating expense, net | (62) | (30) | (171) | (132) | |||
Income before income taxes and equity in earnings of equity method investees | 299 | 237 | 1,175 | 1,130 | |||
Income tax expense | (68) | (40) | (273) | (248) | |||
Equity in earnings of equity method investees, net of taxes | 5 | 8 | 19 | 26 | |||
Net income | 236 | 205 | 921 | 908 | |||
Less: Net income attributable to noncontrolling interests | 14 | 13 | 50 | 54 | |||
Net income attributable to Quest Diagnostics | $ 222 | $ 192 | $ 871 | $ 854 | |||
Earnings per share attributable to Quest Diagnostics' common stockholders: | |||||||
Basic | $ 1.98 | $ 1.72 | $ 7.78 | $ 7.59 | |||
Diluted | $ 1.95 | $ 1.70 | $ 7.69 | $ 7.49 | |||
Weighted average common shares outstanding: | |||||||
Basic | 111 | 112 | 111 | 112 | |||
Diluted | 113 | 113 | 113 | 113 | |||
Quest Diagnostics Incorporated and Subsidiaries Consolidated Balance Sheets December 31, 2024 and 2023 (in millions, except per share data) (unaudited) | |||
December 31, 2024 | December 31, 2023 | ||
Assets | |||
Current assets: | |||
Cash and cash equivalents | $ 549 | $ 686 | |
Accounts receivable, net | 1,304 | 1,210 | |
Inventories | 188 | 190 | |
Prepaid expenses and other current assets | 351 | 286 | |
Total current assets | 2,392 | 2,372 | |
Property, plant and equipment, net | 2,113 | 1,816 | |
Operating lease right-of-use assets | 651 | 602 | |
Goodwill | 8,856 | 7,733 | |
Intangible assets, net | 1,763 | 1,166 | |
Investment in equity method investees | 123 | 135 | |
Other assets | 255 | 198 | |
Total assets | $ 16,153 | $ 14,022 | |
Liabilities and Stockholders' Equity | |||
Current liabilities: | |||
Accounts payable and accrued expenses | $ 1,394 | $ 1,359 | |
Current portion of long-term debt | 602 | 303 | |
Current portion of long-term operating lease liabilities | 173 | 153 | |
Total current liabilities | 2,169 | 1,815 | |
Long-term debt | 5,615 | 4,410 | |
Long-term operating lease liabilities | 535 | 503 | |
Other liabilities | 938 | 876 | |
Redeemable noncontrolling interest | 83 | 76 | |
Stockholders' equity: | |||
Quest Diagnostics stockholders' equity: | |||
Common stock, par value | 2 | 2 | |
Additional paid-in capital | 2,361 | 2,320 | |
Retained earnings | 9,360 | 8,825 | |
Accumulated other comprehensive loss | (88) | (14) | |
Treasury stock, at cost; 51 shares as of both December 31, 2024 and 2023 | (4,857) | (4,826) | |
Total Quest Diagnostics stockholders' equity | 6,778 | 6,307 | |
Noncontrolling interests | 35 | 35 | |
Total stockholders' equity | 6,813 | 6,342 | |
Total liabilities and stockholders' equity | $ 16,153 | $ 14,022 | |
Quest Diagnostics Incorporated and Subsidiaries Consolidated Statements of Cash Flows For the Twelve Months Ended December 31, 2024 and 2023 (in millions) (unaudited) | |||
Twelve Months Ended December 31, | |||
2024 | 2023 | ||
Cash flows from operating activities: | |||
Net income | $ 921 | $ 908 | |
Adjustments to reconcile net income to net cash provided by operating activities: | |||
Depreciation and amortization | 493 | 439 | |
Provision for credit losses | 5 | 1 | |
Deferred income tax provision (benefit) | 13 | (49) | |
Stock-based compensation expense | 88 | 77 | |
Other, net | 15 | 41 | |
Changes in operating assets and liabilities: | |||
Accounts receivable | (71) | (15) | |
Accounts payable and accrued expenses | (67) | (55) | |
Income taxes payable | 16 | (2) | |
Other assets and liabilities, net | (79) | (73) | |
Net cash provided by operating activities | 1,334 | 1,272 | |
Cash flows from investing activities: | |||
Business acquisitions, net of cash acquired | (2,164) | (611) | |
Capital expenditures | (425) | (408) | |
Other investing activities, net | 41 | (42) | |
Net cash used in investing activities | (2,548) | (1,061) | |
Cash flows from financing activities: | |||
Proceeds from borrowings | 1,846 | 2,592 | |
Repayments of debt | (303) | (1,844) | |
Purchases of treasury stock | (151) | (275) | |
Exercise of stock options | 73 | 72 | |
Employee payroll tax withholdings on stock issued under stock-based compensation plans | (24) | (28) | |
Dividends paid | (331) | (314) | |
Distributions to noncontrolling interest partners | (47) | (57) | |
Other financing activities, net | 21 | 14 | |
Net cash provided by financing activities | 1,084 | 160 | |
Effect of exchange rate changes on cash and cash equivalents and restricted cash | (7) | — | |
Net change in cash and cash equivalents and restricted cash | (137) | 371 | |
Cash and cash equivalents and restricted cash, beginning of period | 686 | 315 | |
Cash and cash equivalents and restricted cash, end of period | $ 549 | $ 686 | |
Cash paid during the period for: | |||
Interest | $ 262 | $ 134 | |
Income taxes | $ 256 | $ 317 | |
Notes to Financial Tables
1) The computation of basic and diluted earnings per common share is as follows: |
Three Months Ended December 31, | Twelve Months Ended December 31, | ||||||
2024 | 2023 | 2024 | 2023 | ||||
(in millions, except per share data) | |||||||
Amounts attributable to Quest Diagnostics' common stockholders: | |||||||
Net income attributable to Quest Diagnostics | $ 222 | $ 192 | $ 871 | $ 854 | |||
Less: Earnings allocated to participating securities | 2 | — | 5 | 4 | |||
Earnings available to Quest Diagnostics' common stockholders - basic and diluted | $ 220 | $ 192 | $ 866 | $ 850 | |||
Weighted average common shares outstanding - basic | 111 | 112 | 111 | 112 | |||
Effect of dilutive securities: | |||||||
Stock options and performance share units | 2 | 1 | 2 | 1 | |||
Weighted average common shares outstanding - diluted | 113 | 113 | 113 | 113 | |||
Earnings per share attributable to Quest Diagnostics' common stockholders: | |||||||
Basic | $ 1.98 | $ 1.72 | $ 7.78 | $ 7.59 | |||
Diluted | $ 1.95 | $ 1.70 | $ 7.69 | $ 7.49 | |||
2) The following tables reconcile reported GAAP results to non-GAAP adjusted results: |
Three Months Ended December 31, 2024 | |||||||||||
(dollars in millions, except per share data) | |||||||||||
Operating | Operating | Income tax | Equity in | Net income | Diluted EPS | ||||||
As reported | $ 361 | 13.8 % | $ (68) | $ 5 | $ 222 | $ 1.95 | |||||
Restructuring and integration charges (a) | 17 | 0.6 | (5) | — | 12 | 0.11 | |||||
Other charges (b) | (6) | (0.2) | — | — | (6) | (0.06) | |||||
Gains and losses on investments (c) | — | — | (1) | 4 | 3 | 0.03 | |||||
Other gains (d) | — | — | 1 | — | (3) | (0.02) | |||||
Amortization expense | 37 | 1.4 | (9) | — | 28 | 0.25 | |||||
ETB | — | — | (3) | — | (3) | (0.03) | |||||
As adjusted | $ 409 | 15.6 % | $ (85) | $ 9 | $ 253 | $ 2.23 | |||||
Twelve Months Ended December 31, 2024 | |||||||||||
(dollars in millions, except per share data) | |||||||||||
Operating | Operating | Income tax | Equity in | Net income | Diluted EPS | ||||||
As reported | $ 1,346 | 13.6 % | $ (273) | $ 19 | $ 871 | $ 7.69 | |||||
Restructuring and integration charges (a) | 62 | 0.6 | (15) | — | 47 | 0.42 | |||||
Other charges (b) | 6 | 0.1 | — | — | 5 | 0.04 | |||||
Gains and losses on investments (c) | — | — | (4) | 15 | 11 | 0.10 | |||||
Other gains (d) | — | — | 3 | — | (9) | (0.08) | |||||
Amortization expense | 127 | 1.3 | (32) | — | 95 | 0.84 | |||||
ETB | — | — | (9) | — | (9) | (0.08) | |||||
As adjusted | $ 1,541 | 15.6 % | $ (330) | $ 34 | $ 1,011 | $ 8.93 | |||||
Three Months Ended December 31, 2023 | |||||||||||
(dollars in millions, except per share data) | |||||||||||
Operating | Operating | Income tax | Equity in | Net income | Diluted EPS | ||||||
As reported | $ 267 | 11.7 % | $ (40) | $ 8 | $ 192 | $ 1.70 | |||||
Restructuring and integration charges (a) | 11 | 0.5 | (2) | — | 9 | 0.07 | |||||
Other charges (b) | 33 | 1.4 | (6) | — | 27 | 0.23 | |||||
Amortization expense | 27 | 1.2 | (8) | — | 19 | 0.17 | |||||
ETB | — | — | (2) | — | (2) | (0.02) | |||||
As adjusted | $ 338 | 14.8 % | $ (58) | $ 8 | $ 245 | $ 2.15 | |||||
Twelve Months Ended December 31, 2023 | |||||||||||
(dollars in millions, except per share data) | |||||||||||
Operating | Operating | Income tax | Equity in | Net income | Diluted EPS | ||||||
As reported | $ 1,262 | 13.6 % | $ (248) | $ 26 | $ 854 | $ 7.49 | |||||
Restructuring and integration charges (a) | 43 | 0.5 | (10) | — | 33 | 0.29 | |||||
Other charges (b) | 44 | 0.5 | (8) | — | 36 | 0.31 | |||||
Gains and losses on investments (c) | — | — | (1) | 3 | 2 | 0.02 | |||||
Amortization expense | 108 | 1.2 | (28) | — | 80 | 0.70 | |||||
ETB | — | — | (11) | — | (11) | (0.10) | |||||
As adjusted | $ 1,457 | 15.8 % | $ (306) | $ 29 | $ 994 | $ 8.71 | |||||
(a) | For both the three and twelve months ended December 31, 2024 and 2023, the pre-tax impact represents costs primarily associated with workforce reductions and integration costs incurred in connection with further restructuring and integrating our business. The following table summarizes the pre-tax impact of restructuring and integration charges on our consolidated statements of operations: |
Three Months Ended December 31, | Twelve Months Ended December 31, | ||||||
2024 | 2023 | 2024 | 2023 | ||||
(dollars in millions) | |||||||
Cost of services | $ 8 | $ 4 | $ 27 | $ 16 | |||
Selling, general and administrative | 9 | 7 | 37 | 27 | |||
Other operating (income) expense, net | — | — | (2) | — | |||
Operating income | $ 17 | $ 11 | $ 62 | $ 43 | |||
(b) | For all periods presented, other operating (income) expense, net includes pre-tax (gains)/losses associated with the change in the fair value of the contingent consideration accrual associated with previous acquisitions. For both the three and twelve months ended December 31, 2023, the pre-tax impact also includes a |
Three Months Ended December 31, | Twelve Months Ended December 31, | ||||||
2024 | 2023 | 2024 | 2023 | ||||
(dollars in millions) | |||||||
Cost of services | $ 2 | $ — | $ 2 | $ — | |||
Selling, general and administrative | — | (2) | 2 | 5 | |||
Other operating (income) expense, net | (8) | 35 | 2 | 39 | |||
Operating income | $ (6) | $ 33 | $ 6 | $ 44 | |||
(c) | For all periods presented, the pre-tax impact primarily represents (gains) and losses associated with changes in the carrying value of our strategic investments, recorded in equity in earnings of equity method investees, net of taxes. |
(d) | The twelve months ended December 31, 2024 principally includes a non-recurring |
(e) | For restructuring and integration charges, gains and losses on investments, other charges and gains, and amortization expense, income tax impacts, where recorded, were primarily calculated using combined statutory income tax rates of |
3) For both the three and twelve months ended December 31, 2024, we repurchased 0.9 million shares of our common stock for |
4) The outlook for adjusted diluted EPS represents management's estimates for the full year 2025 before the impact of special items. Further impacts to earnings related to special items may occur throughout 2025. Additionally, the amount of ETB is dependent upon employee stock option exercises and our stock price, which are difficult to predict. The following table reconciles our 2025 outlook for diluted EPS under GAAP to our outlook for adjusted diluted EPS: |
Low | High | ||
Diluted EPS | $ 8.34 | $ 8.59 | |
Restructuring and integration charges (a) | 0.11 | 0.11 | |
Amortization expense (b) | 1.05 | 1.05 | |
Other charges (c) | 0.13 | 0.13 | |
ETB | (0.08) | (0.08) | |
Adjusted diluted EPS | $ 9.55 | $ 9.80 |
(a) | Represents estimated pre-tax charges of |
(b) | Represents estimated pre-tax amortization expenses of |
(c) | Represents estimated pre-tax net losses of |
View original content to download multimedia:https://www.prnewswire.com/news-releases/quest-diagnostics-reports-fourth-quarter-and-full-year-2024-financial-results-provides-guidance-for-full-year-2025-increases-quarterly-dividend-6-7-to-0-80-per-share-302363808.html
SOURCE Quest Diagnostics
FAQ
What was Quest Diagnostics' (DGX) revenue growth in Q4 2024?
How much did Quest Diagnostics increase its dividend in 2025?
What is Quest Diagnostics' (DGX) earnings guidance for 2025?
How many acquisitions did Quest Diagnostics complete in 2024?
What percentage of in-network lives does Quest Diagnostics now cover?
